Novavax (NVAX) closed at $8.48 in the latest trading session, marking a -4.83% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.63%. At the same time, the Dow ...

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at ...

Investing.com -- Novavax Inc (NASDAQ:NVAX) stock gained 2% Tuesday after Shah Capital, the company’s second-largest shareholder, sent a letter to the board urging an immediate strategic review for a ...

Sanofi recently announced an expansion of its licensing agreement with Novavax, granting it broader rights to use Novavax's Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program ...

Prosper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks. Before The Motley Fool, Prosper wrote about investing topics ...

Novavax just signed a lucrative agreement with a biotech giant. Inovio Pharmaceuticals is inching closer to launching its leading candidate. Both companies look risky, but one has a clear edge over ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® ...

Novavax, Inc.'s Sanofi partnership provides much-needed financial support via upfront and milestone payments, stabilizing its finances. Combination vaccines are set to be an essential market, but ...

Novavax's earnings are likely due within the next couple of weeks. The vaccine developer was part of Operation Warp Speed, receiving $1.8bn of funding from the US government to develop a COVID vaccine ...

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...

Five years ago, Novavax (NASDAQ: NVAX) was a little-known clinical-stage biotech whose leading pipeline candidate was an influenza vaccine. Then came the pandemic. The company quickly grew in ...